Free Trial

Cidara Therapeutics (CDTX) Competitors

Cidara Therapeutics logo
$63.96 +0.53 (+0.84%)
As of 12:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CDTX vs. LEGN, RNA, AXSM, ABVX, NUVL, MRUS, CRSP, TGTX, CYTK, and AAPG

Should you be buying Cidara Therapeutics stock or one of its competitors? The main competitors of Cidara Therapeutics include Legend Biotech (LEGN), Avidity Biosciences (RNA), Axsome Therapeutics (AXSM), Abivax (ABVX), Nuvalent (NUVL), Merus (MRUS), CRISPR Therapeutics (CRSP), TG Therapeutics (TGTX), Cytokinetics (CYTK), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry.

Cidara Therapeutics vs. Its Competitors

Legend Biotech (NASDAQ:LEGN) and Cidara Therapeutics (NASDAQ:CDTX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.

Legend Biotech has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500.

Cidara Therapeutics has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Cidara Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Legend Biotech$796.84M8.04-$177.03M-$0.88-39.46
Cidara Therapeutics$1.27M1,277.19-$169.83M-$11.13-5.75

Cidara Therapeutics has a net margin of 0.00% compared to Legend Biotech's net margin of -40.83%. Legend Biotech's return on equity of -32.00% beat Cidara Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Legend Biotech-40.83% -32.00% -20.07%
Cidara Therapeutics N/A -50.81%-42.46%

In the previous week, Legend Biotech had 4 more articles in the media than Cidara Therapeutics. MarketBeat recorded 10 mentions for Legend Biotech and 6 mentions for Cidara Therapeutics. Cidara Therapeutics' average media sentiment score of 0.77 beat Legend Biotech's score of 0.59 indicating that Cidara Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Legend Biotech
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Cidara Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

70.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 35.8% of Cidara Therapeutics shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by company insiders. Comparatively, 7.6% of Cidara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Legend Biotech currently has a consensus price target of $74.22, indicating a potential upside of 113.75%. Cidara Therapeutics has a consensus price target of $64.14, indicating a potential upside of 0.29%. Given Legend Biotech's higher possible upside, equities analysts plainly believe Legend Biotech is more favorable than Cidara Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Legend Biotech
0 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.91
Cidara Therapeutics
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
3.11

Summary

Cidara Therapeutics beats Legend Biotech on 9 of the 17 factors compared between the two stocks.

Get Cidara Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CDTX vs. The Competition

MetricCidara TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.62B$3.10B$5.76B$9.85B
Dividend YieldN/A2.28%6.66%4.49%
P/E Ratio-5.7520.9382.4826.51
Price / Sales1,277.19367.07500.41161.56
Price / CashN/A43.5325.7028.92
Price / Book3.248.0510.816.51
Net Income-$169.83M-$53.35M$3.28B$266.22M
7 Day Performance-1.95%-0.93%-0.43%-1.21%
1 Month Performance2.40%5.97%6.47%3.32%
1 Year Performance465.27%10.33%49.57%23.49%

Cidara Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CDTX
Cidara Therapeutics
3.7117 of 5 stars
$63.96
+0.8%
$64.14
+0.3%
+447.3%$1.62B$1.27M-5.7590News Coverage
LEGN
Legend Biotech
3.5258 of 5 stars
$34.60
-2.7%
$73.00
+111.0%
-37.3%$6.53B$627.24M-39.322,609
RNA
Avidity Biosciences
3.1991 of 5 stars
$45.27
-2.3%
$67.00
+48.0%
+16.1%$5.96B$10.90M-12.72190Positive News
AXSM
Axsome Therapeutics
4.7729 of 5 stars
$116.31
-1.9%
$178.00
+53.0%
+36.1%$5.91B$385.69M-22.94380News Coverage
Positive News
Analyst Forecast
Insider Trade
ABVX
Abivax
3.2547 of 5 stars
$77.46
+0.2%
$92.33
+19.2%
+574.1%$5.84BN/A0.0061News Coverage
Positive News
Short Interest ↓
NUVL
Nuvalent
3.2422 of 5 stars
$74.05
-2.7%
$118.91
+60.6%
-4.9%$5.49BN/A-15.1140News Coverage
Positive News
Analyst Forecast
MRUS
Merus
3.0238 of 5 stars
$65.74
-2.6%
$88.64
+34.8%
+32.0%$5.10B$36.13M-11.9537News Coverage
Positive News
CRSP
CRISPR Therapeutics
3.5882 of 5 stars
$54.13
-0.3%
$71.60
+32.3%
+16.4%$4.94B$37.31M-9.97460Analyst Revision
TGTX
TG Therapeutics
4.3988 of 5 stars
$28.53
-3.1%
$46.25
+62.1%
+40.2%$4.67B$329M77.11290News Coverage
Positive News
CYTK
Cytokinetics
4.1774 of 5 stars
$37.01
-3.5%
$71.58
+93.4%
-8.4%$4.59B$18.47M-7.26250Trending News
Analyst Forecast
Insider Trade
Options Volume
AAPG
Ascentage Pharma Group International
N/A$43.48
-9.2%
N/AN/A$4.45B$134.35M0.00600Positive News
Gap Down
High Trading Volume

Related Companies and Tools


This page (NASDAQ:CDTX) was last updated on 9/4/2025 by MarketBeat.com Staff
From Our Partners